Fate Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 18.88 million compared to USD 65.69 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.68 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.72% | -1.66% | +10.96% |
05-10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
05-10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.96% | 472M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.33% | 21.93B | |
-12.15% | 22.34B | |
-5.52% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023